Pharming Announces US FDA Acceptance for Priority Review of it...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
LEIDEN, The Netherlands, Sep 28, 2022, /PRNewswire-AsiaNet/-- The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiencyPharming Group N.V. ("Pharming" ...
Authors: LATEST ASIANET NEWS RELEASES